ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
56 hedge funds and large institutions have $216M invested in Adaptimmune Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
1% less capital invested
Capital invested by funds: $219M → $216M (-$2.84M)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
Holders
56
Holding in Top 10
1
Calls
$1K
Puts
–
Top Buyers
| 1 | +$39M | |
| 2 | +$1.81M | |
| 3 | +$1.3M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$846K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$679K |
Top Sellers
| 1 | -$4.58M | |
| 2 | -$2.12M | |
| 3 | -$253K | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$189K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$165K |